Building on regulatory submissions elsewhere, the company is looking to gain approval for bevacizumab candidate BAT1706 in Brazil.
A Guangzhou, China, company that has submitted a bevacizumab biosimilar candidate for regulatory approval in China and Europe is moving ahead with a similar filing in Brazil.
Bio-Thera Solutions has developed BAT1706 and recently completed a phase 3 comparative clinical study demonstrating equivalence to the reference product (Avastin) for efficacy, safety, pharmacokinetics, and immunogenicity in patients with advanced nonsquamous non–small cell lung cancer who also received chemotherapy.
The company now has contracted for Biomm SA to submit the regulatory paperwork for BAT1706 in Brazil and handle the product distribution in that market. “This partnership will leverage Biomm’s strong local presence, sales, and marketing capabilities in Brazil,” Bio-Thera said in a statement that also explained that it would handle the product manufacturing side of the partnership, utilizing its biopharmaceutical plant in Guangzhou.
“This partnership is the first to expand Bio-Thera’s presence into Brazil, an important pharmaceutical market for biosimilars and innovative drugs,” Shengfeng Li, CEO of Bio-Thera, said in the statement.
BAT1706 is intended for the treatment of patients with metastatic colorectal cancer; metastatic or locally recurrent breast cancer; locally advanced, metastatic, or recurrent non–small cell lung cancer; metastatic renal cell carcinoma; persistent, recurrent, or metastatic cervical cancer; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Heraldo Marchezini, CEO of Biomm, said his company was eager to expand its activities in the oncology biologics space. "Biomm is committed to expanding its portfolio in biotechnology with a long-term vision, especially in oncology where is critical to expand the access to modern treatments.”
In September 2020, Bio-Thera announced distribution partners for the marketing of BAT1706 in China and Russia. In January, Bio-Thera launched the first adalimumab biosimilar (Qletli) in China.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.